Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Chief Human Resources Officer | February 12, 2021 | February 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date February 12, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.82 · Expires 2031-02-11 | Direct | 11,200 |
Reported balance
After 2021-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-12 · Grant · Acquired 11,200 · Balance 11,200 F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Global Blood Therapeutics, Inc.
Report date October 05, 2022 · Filed October 06, 2022
Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 1
1 source rowRow 1 · 2022-10-05 · Disposition to issuer · Disposed 6,716 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-05 · Disposition to issuer · Disposed 24,180 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-05 · Disposition to issuer · Disposed 15,460 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-05 · Disposition to issuer · Disposed 26,454 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-05 · Disposition to issuer · Disposed 42,400 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.85 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-05 · Disposition to issuer · Disposed 49,600 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.87 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-05 · Disposition to issuer · Disposed 28,628 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.
F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.
F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2022 Filed Oct 6, 2022 16:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,628 | Not disclosed Strike: $29.87 | Not disclosed |
DisclosureSEC source: 0000899243-22-033146 · doc4.xml · derivative · entry 7 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,628 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 49,600 | Not disclosed Strike: $29.85 | Not disclosed |
DisclosureSEC source: 0000899243-22-033146 · doc4.xml · derivative · entry 6 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,600 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerRestricted Stock Units · Derivative | 42,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033146 · doc4.xml · derivative · entry 5 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,400 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6 · price: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. F6 · derivative.exercise_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. F6 · derivative.expiration_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerRestricted Stock Units · Derivative | 26,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033146 · doc4.xml · derivative · entry 4 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,454 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerRestricted Stock Units · Derivative | 15,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033146 · doc4.xml · derivative · entry 3 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,460 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerRestricted Stock Units · Derivative | 24,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033146 · doc4.xml · derivative · entry 2 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,180 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerCommon Stock | 6,716 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033146 · doc4.xml · nonDerivative · entry 1 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 19:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,208 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030477 · doc4.xml · derivative · entry 5 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,460 Underlying: Common Stock · 2,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 19:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 8,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030477 · doc4.xml · derivative · entry 4 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,180 Underlying: Common Stock · 8,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in 6 semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in 6 semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 19:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 3,552 | $68.15 | $242,068.80 |
DisclosureSEC source: 0000899243-22-030477 · doc4.xml · nonDerivative · entry 3 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,716 F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 10,268 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 19:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-030477 · doc4.xml · nonDerivative · entry 2 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 19:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 8,060 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-030477 · doc4.xml · nonDerivative · entry 1 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:02 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to buy) · Derivative | 28,628 | $0.00 Strike: $29.87 | $0.00 |
DisclosureSEC source: 0000899243-22-009249 · doc4.xml · derivative · entry 3 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,628 Underlying: Common Stock · 28,628 shares Expires 2032-02-28 F4 · derivative.exercise_date: The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:02 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 17,668 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009249 · doc4.xml · derivative · entry 2 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,668 Underlying: Common Stock · 17,668 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:02 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 17,668 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009249 · doc4.xml · derivative · entry 1 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,668 Underlying: Common Stock · 17,668 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F2 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 49,600 | $0.00 Strike: $29.85 | $0.00 |
DisclosureSEC source: 0000899243-21-034986 · doc4.xml · derivative · entry 3 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,600 Underlying: Common Stock · 49,600 shares Expires 2031-08-31 F4 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on August 2, 2022 and in 12 equal quarterly installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 42,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034986 · doc4.xml · derivative · entry 2 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,400 Underlying: Common Stock · 42,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:00 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 32,240 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034986 · doc4.xml · derivative · entry 1 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,240 Underlying: Common Stock · 32,240 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in six semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F2 · derivative.expiration_date: The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in six semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 11,200 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000899243-21-007023 · doc4.xml · derivative · entry 1 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Underlying: Common Stock · 11,200 shares Expires 2031-02-11 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:30 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0000899243-21-002193 · doc4.xml · derivative · entry 1 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:50 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantIncentive Stock Option (right to buy) · Derivative | 40,391 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-20-025644 · doc4.xml · derivative · entry 3 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,391 Underlying: Common Stock · 40,391 shares Expires 2030-09-17 F5 · derivative.exercise_date: 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:50 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantEmployee Stock Option (right to buy) · Derivative | 15,450 | Not disclosed Strike: $5.97 | Not disclosed |
DisclosureSEC source: 0000899243-20-025644 · doc4.xml · derivative · entry 2 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,450 Underlying: Common Stock · 15,450 shares Expires 2029-10-15 F4 · price: Received in exchange for an employee stock option to acquire 124,600 shares of common stock of Old Adicet for $0.740 per share in connection with the Merger. F3 · derivative.exercise_date: 1/48th of the option vests on each of the forty-eight (48) monthly anniversaries of October 15, 2019, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:50 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantEmployee Stock Option (right to buy) · Derivative | 18,600 | Not disclosed Strike: $2.26 | Not disclosed |
DisclosureSEC source: 0000899243-20-025644 · doc4.xml · derivative · entry 1 Krehlik Carrie · CIK 0001823899 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2027-12-13 F2 · price: Received in exchange for an employee stock option to acquire 150,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.280 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." F1 · derivative.exercise_date: 25% of the option vested on November 27, 2018, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.